ge biopharma busi acquisit boost growth
maintain buy rate upgrad tp
estim tp base forward
price-to-earnings multipl adjust ep
expect price/sal give upsid
potenti estim
top line revenu growth
danah report strong growth revenu earn
year total revenu increas
due strong growth across segment compani
continu captur market share mani busi
new product innov enhanc commerci
execut net earn per
dilut share repres y/i decreas non-gaap
ep per share repres y/i increas
continu evolv higher growth compani
announc acquisit complet
ipo subsequ split-off dental segment
ge biopharma call cytiva complet
acquisit good core revenu growth
acceler rel busi perform
past coupl year
cash cash equival
end last
sequenti
compani name corporationtickerdhrstock ratingbuyunchangedindustri viewoverweightpositivepric downgradecmp apr potenti volum volum ep margin margin ttm per share growth profit ttm ttm earn growth corp april
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
total revenu life scienc segment total
rise y/i result
driven gain acquir asset growth
core sale partial off-set advers impact
revenu diagnost segment gross
increas y/i improv came
back rise core sale partial
off-set neg impact foreign-curr
revenu environment appli solut
segment total rise y/i uptick
attribut growth core sale howev
foreign-curr translat advers impact
share price surg januari
result howev stock tumbl
march due pandem
danah corpor announc
expect revenu growth non-gaap core
revenu growth compani anticip
posit result three report segment
particular strength cepheid radiomet
pall chemtreat busi
said good start year saw
meaning slowdown demand toward end
march quarter particularli instrument-
orient busi pandem spread
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date apr ex-dividend date last split factor new per last split date jul inform danah corp april
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
non- reconcili refer page
total revenu growth growth gross gross gener sg oper oper oper expens incom interest expens incom incom tax incom net earn continu earn discontinu oper net incom net mandatori convert prefer stock net incom net incom y/i incom q/q incom per share basic ep growth outstand estim annual incom statement itemsactu quarterli actual annual danah corp april
 equival account total prepaid expens current asset total current asset gross properti plant accumul net properti plant long-term long-term total account accru current portion lt current incom tax unearn revenu current total current long-term unearn revenu pension post-retir capit -other non-curr total prefer stock -total prefer -common addit paid retain comprehens incom total common minor total total liabil balanc sheet itemsactu quarterli actual annual corp april
oper cash flow continu oper increas
compar increas due higher net earn includ higher non-
cash charg depreci amort stock compens impact non-cash
discret incom tax charg net higher cash use fund trade account receiv
inventori trade account payabl
net cash use invest activ compar
net cash provid financ activ compar
increas due public offer compani common prefer stock
issuanc debt compani
non- non- non- compens non- invest income/loss non- income/loss non- trade prepay trade accru defer continu oper activ discontinu oper oper activ properti plant dispos properti plant busi invest invest continu invest discontinu invest invest of/pay common stock of/pay prefer stock of/repay short term debt of/repay long term debt movement non-controlling/minor dividend interest financ continu financ discontinu financ financ equival end exchang rate equival begin statementactu quarterli actual annual corp april
show strong growth core revenu growth
solid margin expans cash flow also complet split-off
dental segment announc acquisit biopharma busi
compar
total revenu increas compar
cog increas
compar gross profit increas
compar gross profit margin
compar
sg expens increas compar
sg expens sale
compar
 expens increas compar
 expens sale
compar
oper profit increas compar
oper profit margin
compar
compar
expens net compar incom
net interest expens
compar interest incom
compar loss earli extinguish borrow
provis incom tax compar
effect tax rate
compar
net earn continu oper increas
compar ep
compar non-gaap ep
compar
total revenu increas compar
cog increas compar
increas due impact higher y/i sale
volum includ sale recent acquir busi product mix
higher freight tariff cost partial off-set increas leverag certain
manufactur cost increment y/i cost save associ
continu product improv initi taken
gross profit increas compar
gross profit margin compar
gross margin decreas due impact product mix higher
freight tariff cost
decreas partial off-set impact higher year-over-year sale
volum includ sale recent acquir busi increas
leverag certain manufactur cost increment year-over-year cost
save associ continu product improv initi
taken
sg expens increas compar
sg expens sale decreas
compar decreas sg sale
driven increas leverag compani gener administr
cost base result higher sale volum continu
product improv taken
decreas partial off-set continu invest sale
market growth initi transact cost integr prepar
cost associ anticip ge biopharma acquisit
increas sg sale
compar
increas
compar
compar
decreas
compar
 expens increas compar
 expens sale increas slightli
compar expens sale
increas slightli y/i due increas compani new product
develop initi roughli correspond increas sale
oper profit increas compar
oper profit margin compar
oper profit margin comparison favor impact
higher core sale volum increment y/i cost save
associ continu product improv initi taken
net increment y/i cost associ variou
new product develop sale servic market growth
invest impact foreign exchang rate
acquisition-rel transact cost fair valu adjust
inventori relat acquisit
oper profit margin comparison unfavor impact
increment net dilut effect acquir busi
transact cost integr prepar cost relat
anticip acquisit busi
gain resolut acquisition-rel matter
loss earli extinguish borrow incom
net compar interest expens
compar interest incom
compar
provis incom tax increas compar
effect tax rate compar
effect tax rate also includ net
tax charg relat primarili chang estim associ prior
period uncertain tax posit audit settlement envista disposit cost
net releas reserv uncertain tax posit due expir
statut limit releas valuat allow associ certain
foreign tax credit tax benefit result chang tax law excess tax
benefit stock-bas compens
net earn decreas compar
ep compar
non-gaap ep compar
danah report segment includ life scienc diagnost
environment appli solut graph repres revenu
contribut segment
life scienc segment contribut total revenu follow
diagnost segment contribut total revenu
environment appli solut contribut total revenu
compar
contribut
total revenu
total revenu increas compar
oper profit increas
compar oper margin
increas compar
total revenu increas compar
price increas segment contribut
revenu growth y/i basi compar
reflect compon chang core revenu growth
sale filtrat separ purif technolog increas
across major geographi y/i basi led growth
biopharmaceut aerospac fluid technolog asset protect
end-market partial off-set soft microelectron end-
sale microscopi product grew y/i basi across major
product line led north america high-growth market
particularli china sale y/i flow cytometri particl count
product grew across major geographi end-market
sale busi broad rang mass spectromet increas
y/i basi led strong core sale growth high-growth market
particularli china rest asia partial off-set lower
demand north america growth led demand
pharmaceut academ end-market servic offer
partial off-set lower core sale clinic end-market
profit increas
compar
revenu increas
compar
sale growth acquisit growth due
acquisit april provid addit sale
earn growth opportun segment expand segment
product line divers includ new product servic offer
area genom consum idt revenu grew y/i
basi across major product line geographi driven north
oper profit increas compar
oper profit margin increas
compar oper profit margin comparison
favor impact
higher core sale volum increment y/i cost save
associ continu product improv initi
taken net increment y/i cost associ
variou new product develop sale market growth
invest impact foreign exchang rate
acquisition-rel transact cost fair valu adjust
inventori relat acquisit
oper profit margin comparison unfavor impact
increment net dilut effect acquir busi
gain resolut acquisition-rel matter
increas
compar
increas
compar
total revenu increas compar
oper profit increas
compar oper margin
increas compar
total revenu increas compar
sale growth geograph core
sale clinic lab busi increas y/i basi due continu
demand high-growth market led china north america
partial off-set modest declin western europ
increas demand clinic lab busi mainli driven
immunoassay chemistri autom product line sale
molecular diagnost busi increas y/i basi major
product line across major geographi
compar
increas
compar
sale growth y/i acut care diagnost busi driven
continu strong sale blood ga immunoassay product line
primarili china western europ japan north america
increas demand advanc stain core histolog product line
drove major y/i core sale growth patholog diagnost
oper profit increas compar
oper profit margin increas
compar increas oper margin
due higher core sale volum increment y/i cost save
associ continu product improv initi taken
net increment y/i cost associ variou new
product develop sale servic market growth invest
impact foreign exchang rate
total revenu increas compar
oper profit increas
compar oper margin
increas compar
total revenu increas compar
sale growth price increas
segment contribut sale growth y/i basi
compar reflect compon chang
sale segment water qualiti busi grew mid-singl
digit rate compar sale y/i
analyt instrument product line increas driven demand
north america western europ high-growth market partial off-set
lower core sale china primarili result strong regulatori driven
demand prior year
revenu growth y/i busi chemic treatment solut
product line driven demand oil ga primari metal food
beverag commerci industri end-market geograph
core revenu growth y/i chemic treatment solut product line
driven north america latin america
sale growth y/i acut care diagnost busi driven
continu strong sale blood ga immunoassay product line
primarili china western europ japan north america increas
demand advanc stain core histolog product line drove
major y/i core sale growth patholog diagnost busi
increas
compar
acut care
diagnost busi
driven continu
strong sale blood ga
immunoassay
product line china
north america
sale busi ultraviolet water disinfect product line
increas across major end-market y/i basi driven
complet sever municip project geograph y/i core revenu
growth ultraviolet water disinfect product led north america
china
sale segment product identif busi grew low-
singl digit rate compar y/i core revenu
growth mark code equip relat consum
driven demand north america western europ high-growth
sale busi packag color solut increas y/i
driven increas demand north america western europ high
oper profit increas compar
oper margin increas
compar
oper profit margin comparison favor impact higher
core sale volum increment year-over-year cost save
associ continu product improv initi taken
impact foreign exchang rate net increment
y/i cost associ variou new product develop sale
servic market growth invest
oper profit margin comparison unfavor impact
increment net dilut effect acquir busi
increas
compar
increas
compar
guidanc conclus
compani anticip dilut net earn per share
rang non-gaap adjust dilut net earn per share
rang
compani anticip dilut net earn per share
rang non-gaap adjust dilut net earn per share
assum non-gaap core revenu growth
estim result includ impact earn
pend acquisit expect close
first quarter
tremend year growth revenu growth
adjust ep revenu increas non-gaap core
revenu growth net earn per dilut
share repres y/i decreas non-gaap adjust dilut net
earn per share per share repres
increas
growth beckman life scienc mid-singl digit strength
across major geographi product line finish anoth
great year beckman busi grew high singl digit surpass
billion annual revenu first time
diagnost revenu increas quarter core revenu growth
diagnost team deliv core revenu growth
continu market share gain achiev last year
continu captur market share mani busi new
product innov enhanc commerci execut addit
compani complet split-off dental platform decemb
announc pend acquisit ge biopharma busi
anticip
share rang
tremend
year growth
revenu growth
adjust ep
non- reconcili
non- reconcili
non- reconcili
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
gross margin compar
oper margin compar
net margin compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth corp april
mrqgross mrqcog mrqoper mrqsg mrqnet mrqr sale danah corp april
inv flow sale
mrqyoy growth revenu growthoper incom growthep mrqcapex salescap ex salesfre mrq ratio growth yoy oper growth yoy free growth mrqfinanci mrqreturn mrqreturn asset danah corp april
roe respect roe
averag oper median roe howev roe declin
due declin net margin financi leverag
net margin net margin
declin due increas oper expens
asset turnov respect
leverag respect
financi leverag increas due increas debt due acquisit
dupont analysi roe healthcar sector roe roe
driven high net margin financi leverag
return invest capit
capit effici ratio use measur firm abil creat valu stakehold
debt equiti firm expect continu gener posit excess return new invest
futur see valu increas growth increas
dhr respect decreas
due increas long-term debt
dhr averag oper median dhr
healthcar sector dhr wacc show compani
use invest capit effect
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom net net margin prefer dividends- annual itemsquarterli item danah corp april
balanc sheet item
outstand equival market debt common prefer stock- purchas properti plant sale properti plant purchas sale business- purchas investment- sale issuanc repurchas stock- net issuanc prefer stock- net issuanc net chang capit free corp april
current price-to-earnings multipl due increas stock
price averag price-to-earnings expect forward price-to-earnings multipl
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdersharesd report outvaluevanguard group inc price row associ fmr wellington manag compani massachusett servic morgan america northern trust top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard vanguard specialized-dividend growth price row capit apprciat fund spdr etf mf seri trust i-mf valu vanguard institut fund-institut fidel contrafund price row chip growth fund fidel competit
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
consensu view analyst trend stock
rate expect
compar
 growth
rate
dhr forward price-to-earnings
higher
dhr avgfive-year growth forecast usdgrowth high day day day estim comparisondhrindustri avg avgprice/earn yield corp april
consensu view analyst trend stock
averag earn estim current
qtr next
qtr
sale growth estim current qtr
next qtr
averag revenu estim current
qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last daysn/an/an/an/aup last last daysobsoleteobsoleteobsoleteobsoletedown last dayscurr growth ratescurr surprisescurr corp april
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
stock price show volatil quarter plung march current
trade
stock gave neg return period
stock price volatil show upward trend novemb plung
march
stock gave neg return past one year rang stock
stock price shown upward trend sinc year
stock gave return period
revenu increas strong growth segment compani complet
spin-off dental busi announc acquisit busi recommend
buy rate tp
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
